
Phase 3 OASIZ-301 findings show that investigational dazodalibep improved systemic disease activity in adults with Sjögren disease, with reduced patient-reported dryness at 1 dosing schedule. ow.ly/u2eu5106yRv @SjogrensOrg @ACRheum #Sjogrens #Rheumatology #AutoimmuneDisease



